LVAD Panel Review Raises Profile Of Medicare Cost Effectiveness Evaluation
This article was originally published in The Gray Sheet
Executive Summary
The cost-effectiveness of new therapies should be considered by CMS during the Medicare coverage process, according to some members of the Medicare Coverage Advisory Committee